专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005023202A2 TUMOR SUPPRESSOR LKB1 KINASE DIRECTLY ACTIVATES AMP-ACTIVATED KINASE 审中-公开
标题翻译：肿瘤抑制剂LKB1激酶直接激活激活激酶
公开(公告)号：WO2005023202A2
公开(公告)日：2005-03-17
申请号：PCT/US2004/029437
申请日：2004-09-09
申请人： BETH ISRAEL DEACONESS MEDICAL CENTER, INC. , DANA-FARBER CANCER INSTITUTE, INC. , CANTLEY, Lewis, C. , SHAW, Reuben, J. , BARDEESY, Nabeel , DEPINHO, Ronald, A.
发明人： CANTLEY, Lewis, C. , SHAW, Reuben, J. , BARDEESY, Nabeel , DEPINHO, Ronald, A.
IPC分类号： A61K
CPC分类号： C12Q1/485 , G01N33/573 , G01N33/574 , G01N2333/9015 , G01N2333/91215 , G01N2500/02 , G01N2800/042
摘要： The invention relates to modulation of LKB1 or AMP kinase protein activity for treating disorders including diabetes and cancer. The invention also relates to screening for agents that modulate the activity of LKB1 or AMP kinase protein, which are useful in the treatment of diabetes and cancer, as well as preparing compounds for treatment of diabetes and cancer.
摘要翻译：本发明涉及用于治疗包括糖尿病和癌症在内的疾病的LKB1或AMP激酶蛋白活性的调节。本发明还涉及筛选调节可用于治疗糖尿病和癌症的LKB1或AMP激酶蛋白的活性以及制备用于治疗糖尿病和癌症的化合物的活性的试剂。

2. 发明申请

WO2006020755A2 METHODS FOR IDENTIFYING DIABETES THERAPEUTICS 审中-公开
标题翻译：鉴定糖尿病治疗方法
公开(公告)号：WO2006020755A2
公开(公告)日：2006-02-23
申请号：PCT/US2005/028523
申请日：2005-08-10
申请人： BETH ISRAEL DEACONESS MEDICAL CENTER, INC. , CANTLEY, Lewis, C. , SHAW, Reuben, J. , MANNING, Brendan, D.
发明人： CANTLEY, Lewis, C. , SHAW, Reuben, J. , MANNING, Brendan, D.
IPC分类号： C12Q1/48 , G01N33/68 , A61K31/00
CPC分类号： G01N33/6893 , C12Q1/485 , G01N2800/042
摘要： The invention relates to inhibition of mTOR, p70S6K1 or Rheb kinase activity for treating disorders including diabetes. The invention also relates to screening for agents that inhibit the activities of mTOR, p70S6K1 or Rheb proteins, which are useful in the treatment of diabetes, as well as preparing compounds for treatment of diabetes.
摘要翻译：本发明涉及抑制mTOR，p70S6K1或Rheb激酶活性来治疗包括糖尿病在内的疾病。本发明还涉及抑制可用于治疗糖尿病的mTOR，p70S6K1或Rheb蛋白的活性的药剂的筛选，以及制备用于治疗糖尿病的化合物。

3. 发明申请

WO2012112245A1 MODULATION OF PHOSPHATIDYLINOSITOL-5-PHOSPHATE-4-KINASE ACTIVITY 审中-公开
标题翻译：磷酸二钙磷酸酯-4-激酶活性的调节
公开(公告)号：WO2012112245A1
公开(公告)日：2012-08-23
申请号：PCT/US2012/021266
申请日：2012-01-13
申请人： BETH ISRAEL DEACONESS MEDICAL CENTER, INC. , EMERLING, Brooke , SASAKI, Atsuo , CANTLEY, Lewis, C. , HUROV, Jonathan
发明人： EMERLING, Brooke , SASAKI, Atsuo , CANTLEY, Lewis, C. , HUROV, Jonathan
IPC分类号： C12Q1/48 , C07H21/04
CPC分类号： C12Q1/485 , A61K31/7105 , G01N2500/02 , G01N2500/10
摘要： The invention features methods for identifying compounds that modulate the activity of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K). Inhibitors of PI5P4K can be used in, for example, the treatment or prevention of cell proliferation disorders (e.g., the prevention of tumor cell growth in p53 mutated cancers).
摘要翻译：本发明的特征在于鉴定调节磷脂酰肌醇5-磷酸4-激酶（PI5P4K）的活性的化合物的方法。 PI5P4K的抑制剂可用于例如治疗或预防细胞增殖紊乱（例如，预防p53突变的癌症中的肿瘤细胞生长）。

4. 发明申请

WO2008112311A1 METHODS FOR IDENTIFYING DIABETES AND OBESITY THERAPEUTICS 审中-公开
标题翻译：识别糖尿病和肥胖症治疗方法
公开(公告)号：WO2008112311A1
公开(公告)日：2008-09-18
申请号：PCT/US2008/003440
申请日：2008-03-14
申请人： WASHINGTON UNIVERSITY , BETH ISRAEL DEACONESS MEDICAL CENTER, INC. , HUROV, Jonathan, B. , PIWNICA-WORMS, Helen , CANTLEY, Lewis, C.
发明人： HUROV, Jonathan, B. , PIWNICA-WORMS, Helen , CANTLEY, Lewis, C.
IPC分类号： C07H21/04 , C12Q1/68
CPC分类号： C12N15/1137 , C12N9/1205 , C12N2310/14 , C12Q1/485 , C12Y207/01037 , G01N2500/04 , G01N2800/042 , G01N2800/044
摘要： The invention relates to inhibition of Par- 1b kinase activity for treating disorders including diabetes and obesity. The invention also relates to screening for compounds or compositions that inhibit the kinase activity of Par- 1b protein, which compounds and compositions are useful in the treatment of diabetes and obesity, as well as preparing compounds for treatment of diabetes and obesity.
摘要翻译：本发明涉及抑制Par-1b激酶活性用于治疗包括糖尿病和肥胖症的疾病。本发明还涉及筛选抑制Par-1b蛋白激酶活性的化合物或组合物，该化合物和组合物可用于治疗糖尿病和肥胖症，以及制备用于治疗糖尿病和肥胖症的化合物。

5. 发明申请

WO2003064451A3 MODULATION OF TYPE IIβ PHOSPHOINOSITIDE PHOSPHATE KINASE 审中-公开
公开(公告)号：WO2003064451A3
公开(公告)日：2003-08-07
申请号：PCT/US2003/003065
申请日：2003-02-03
申请人： BETH ISRAEL DEACONESS MEDICAL CENTER, INC. , CANTLEY, Lewis, C. , LAMIA, Katja, A. , RAMEH, Lucia , KAHN, Barbara , PERONI, Odile
发明人： CANTLEY, Lewis, C. , LAMIA, Katja, A. , RAMEH, Lucia , KAHN, Barbara , PERONI, Odile
IPC分类号： C12Q1/68
摘要： The invention provides methods for modulating type IIβ phosphoinisitide phosphate kinase (PIPKIIβ) activity for treating PIPKIIβ-associated disorders. The invention also provides methods of identifying candidate agents for treating PIPKIIβ-associated disorders.

6. 发明申请

WO2014015118A1 METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS 审中-公开
标题翻译：诊断和治疗细胞增殖性疾病的方法和组合
公开(公告)号：WO2014015118A1
公开(公告)日：2014-01-23
申请号：PCT/US2013/051046
申请日：2013-07-18
申请人： BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
发明人： CANTLEY, Lewis, C. , DENICOLA, Gina
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/156
摘要： In general, the invention features compositions and methods for treating cellular proliferative disorders. This invention is based on the discovery that nicotinamide nucleotide transhydrogenase (NNT) is amplified in cancer tissue (e.g., lung cancer tissue), that NNT is overexpressed at the protein and mRNA level in non-small cell lung carcinoma cells (NSCLC cells), and that inhibition of NNT both induces cell death in NNT-amplified NSCLC cell lines and inhibits proliferation of non-amplified cell lines. Accordingly, the invention features methods of diagnosing cancer (e.g., NSCLC) by determining whether the NNT gene is amplified, or if NNT is overexpressed, in a sample (e.g., a tumor or blood sample). Furthermore, the invention features methods of treating cancer (e.g., NSCLC) using inhibitors of NNT (e.g., RNAi compounds, antagonistic antibodies, or small molecule inhibitors).
摘要翻译：通常，本发明的特征在于用于治疗细胞增殖性疾病的组合物和方法。本发明基于在癌组织（例如肺癌组织）中扩增烟酰胺核苷酸转氢酶（NNT）的发现，NNT在非小细胞肺癌细胞（NSCLC细胞）中在蛋白质和mRNA水平上过表达，并且NNT的抑制均诱导NNT扩增的NSCLC细胞系中的细胞死亡并抑制未扩增的细胞系的增殖。因此，本发明的特征在于在样品（例如肿瘤或血液样品）中通过确定NNT基因是否被扩增，或者NNT是否过表达来诊断癌症（例如NSCLC）的方法。此外，本发明的特征在于使用NNT抑制剂（例如RNAi化合物，拮抗性抗体或小分子抑制剂）治疗癌症（例如NSCLC）的方法。

7. 发明申请

WO2013049581A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASES 审中-公开
标题翻译：用于治疗增殖性疾病的组合物和方法
公开(公告)号：WO2013049581A1
公开(公告)日：2013-04-04
申请号：PCT/US2012/057934
申请日：2012-09-28
申请人： BETH ISRAEL DEACONESS MEDICAL CENTER INC.
发明人： WULF, Gerburg , CANTLEY, Lewis, C.
IPC分类号： A61K31/00
CPC分类号： A61K31/5377 , A61K31/4439 , A61K31/502 , A61K45/06
摘要： The present invention relates to pharmaceutical compositions that contain PI3K inhibitors (e.g., PBKa-specific inhibitors) and PARP inhibitors. The invention also provides methods for the treatment of proliferative diseases such as cancer (e.g., breast cancer) by administering the composition(s) to a subject.
摘要翻译：本发明涉及含有PI3K抑制剂（例如，PBKα特异性抑制剂）和PARP抑制剂的药物组合物。本发明还提供了通过向受试者施用组合物来治疗增殖性疾病如癌症（例如乳腺癌）的方法。

8. 发明申请

WO2008156701A3 HYDROXAMATE INHIBITORS OF INSULIN-DEGRADING ENZYME AND USES THEREOF 审中-公开
公开(公告)号：WO2008156701A3
公开(公告)日：2008-12-24
申请号：PCT/US2008/007447
申请日：2008-06-13
申请人： THE BRIGHAM AND WOMEN'S HOSPITAL, INC. , PRESIDENT AND FELLOWS OF HARWARD COLLEGE , YALE UNIVERSITY , LEISSRING, Malcolm, A. , SELKOE, Dennis , CUNY, Gregory, D. , CHOI, Sungwoon , STEIN, Ross, L. , TURK, Benjamin , CANTLEY, Lewis, C.
发明人： LEISSRING, Malcolm, A. , SELKOE, Dennis , CUNY, Gregory, D. , CHOI, Sungwoon , STEIN, Ross, L. , TURK, Benjamin , CANTLEY, Lewis, C.
IPC分类号： C07C237/04
摘要： The present invention provides a novel therapeutic approach for the prevention and treatment of infections and for the treatment of diabetes wherein the degradation of insulin is reduced through inhibition of insulin-degrading enzyme (IDE) by hydroxamate inhibitors.

9. 发明申请

WO2008127710A2 METHODS FOR TREATING CANCER RESISTANT TO ERBB THERAPEUTICS 审中-公开
标题翻译：治疗ERBB治疗的抗癌方法
公开(公告)号：WO2008127710A2
公开(公告)日：2008-10-23
申请号：PCT/US2008/004804
申请日：2008-04-11
申请人： DANA FARBER CANCER INSTITUTE , BETH ISRAEL DEACONESS MEDICAL CENTER , MASSACHUSETTS GENERAL HOSPITAL , JANNE, Pasi, A. , ENGELMAN, Jeffrey , CANTLEY, Lewis, C.
发明人： JANNE, Pasi, A. , ENGELMAN, Jeffrey , CANTLEY, Lewis, C.
IPC分类号： A61K45/06 , A61K39/395 , A61K31/517 , A61K31/404 , A61P35/00
CPC分类号： C12Q1/6886 , A61K31/404 , A61K31/517 , A61K39/395 , A61K45/06 , C12Q2600/106 , C12Q2600/156
摘要： Provided herein are methods for treating cancer that is resistant to treatment with an anti- ErbB therapeutic agent and which is associated with an activating MET gene mutation or a MET gene amplification. The methods involve administering to a subject a combination of an anti- ErbB therapeutic and an anti-MET therapeutic. Also provided are methods for reducing ErbB mediated signaling or PI3 kinase mediated signaling in a cancer cell.
摘要翻译：本文提供了用于治疗对用抗ErbB治疗剂治疗有抗性并且与活化MET基因突变或MET基因扩增相关的癌症的方法。该方法涉及向受试者施用抗ErbB治疗剂和抗MET治疗剂的组合。还提供了用于减少癌细胞中ErbB介导的信号传导或PI3激酶介导的信号传导的方法。

10. 发明申请

WO2004046317A2 PRODUCTS AND PROCESSES FOR MODULATING PEPTIDE-PEPTIDE BINDING DOMAIN INTERACTIONS 审中-公开
标题翻译：调节肽 - 肽结合域相互作用的产物和方法
公开(公告)号：WO2004046317A2
公开(公告)日：2004-06-03
申请号：PCT/US2003/036392
申请日：2003-11-14
申请人： MASSACHUSETTS INSTITUE OF TECHNOLOGY , YAFFE, Michael, B. , ELIA, Andrew, E.H. , RELLOS, Peter , CANTLEY, Lewis, C. , SMERDON, Stephen, J. , MANCKE, Isaac
发明人： YAFFE, Michael, B. , ELIA, Andrew, E.H. , RELLOS, Peter , CANTLEY, Lewis, C. , SMERDON, Stephen, J. , MANCKE, Isaac
IPC分类号： C12N
CPC分类号： C12N9/1205 , A61K38/00 , C07K14/4702 , C07K2299/00 , C12N15/1055 , Y02A90/24 , Y02A90/26
摘要： The present invention relates to therapeutic compounds and methods of use of these therapeutic compounds for treating cellular proliferative disorders. The invention also provides three-dimensional structures of a Polo-like kinase and methods for designing or selecting small molecule inhibitors using these structures, and the therapeutic use of such compounds. The invention also includes a method for identifying novel phosphopeptide-binding domains.
摘要翻译：本发明涉及治疗化合物和这些治疗化合物用于治疗细胞增殖性疾病的方法。本发明还提供了Polo样激酶的三维结构以及使用这些结构设计或选择小分子抑制剂的方法，以及这些化合物的治疗用途。本发明还包括鉴定新的磷酸肽结合结构域的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式